Written Answer · 2023-05-08 · Parliament 14
Credibility and Adoption of AI-based Diagnostic Solutions
質疑はAI診断ソリューションの信頼性とその広範な適用における規制上の考慮に焦点を当てています。政府の回応は、シンガポールが医療領域におけるAIの広範な適用を既に進めていることを指摘し、安全性、臨床有効性、および費用対効果が採用の前提条件であることを強調し、既存の規制フレームワークと今後発布される統治ガイドラインを紹介し、倫理的な問題にも関心を向けています。核心的な争点は、技術革新と安全性規制のバランスをいかに取るかにあります。
重要なポイント
- • AI widely used in healthcare
- • Safety and efficacy as preconditions
- • Strengthen regulation and ethics
安全で有効なAI医療応用を支援する
AI診断の信頼性と規制への注目
AI医療規制枠組みの強化
“The Ministry of Health (MOH) is open to the use of AI technologies in healthcare where they are proven to be safe, clinically efficacious and cost-effective.”
参加者 (2)
英語原文
SPRS Hansard · Fetched: 2026-05-02
39 Assoc Prof Jamus Jerome Lim asked the Minister for Health (a) whether the Ministry has explored the credibility of AI-based diagnostic solutions; and (b) if so, what are the regulatory considerations that will be most important if there are more widespread adoption of such technologies.
Mr Ong Ye Kung : Artificial intelligence (AI) is ubiquitous and being used in healthcare in Singapore. For example, it is used in JARVISDHL, a programme by SingHealth and NUS to prevent diabetes, hypertension, hyperlipidemia. It is the engine for SELENA+ (Singapore Eye LEsioN Analyzer plus) to diagnose diabetic retinopathy. It is also used for diagnosis and management of cardiovascular and chronic diseases. It is deployed in health apps for preventive care, as well as in pharmaceutical research.
The Ministry of Health (MOH) is open to the use of AI technologies in healthcare where they are proven to be safe, clinically efficacious and cost-effective. With the rapid advancement of AI technology, we believe many treatments using AI will emerge. The challenge is to embrace and encourage them, while ensuring the safe adoption and deployment of AI in healthcare. To do so, we have progressively put in place safeguards over the past few years.
The MOH’s AI in Healthcare Guidelines guide AI Medical Device (AI-MD) developers and implementers on the good practices they should adopt in rolling out such clinical services to patients.
The Health Sciences Authority regulates multiple aspects of AI-MD development as part of its medical device registration process to ensure the quality, safety and efficacy of AI-MDs and requires continued post-market surveillance to ensure continued real-world effectiveness.
MOH will be issuing an AI Governance Framework for healthcare that recommends detailed development and implementation-level good practices, such as risk prompts to help identify risks, and controls for risk mitigation.
The Bioethics Advisory Committee has also issued a draft advisory report and recommendations on the ethical use of big data and AI in human biomedical research on 2 May 2023 for public consultation.
MOH will continue to study international best practices, consolidate and develop our AI governance framework.